Gniadecki R, et al. - The long-term effectiveness of adalimumab in patients with psoriasis with flexibility was determined to escalate and de-escalate between every other week (EOW) and every week (EW) dosing. Researchers noted that the achievement and long-term maintenance of clinical improvement were permitted through optimizing therapy by temporarily increasing the dosing of adalimumab to EW in subjects with psoriasis and an inadequate response to adalimumab 40 mg EOW.